DeepMed Research

National Heart, Lung, and Blood Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)

Conditions: Heart Failure

First Posted Date: 2024-02-28

Last Posted Date: 2025-05-21

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 2000

Registration Number: NCT06280820

Locations: 🇺🇸
INOVA Fairfax Hospital, Falls Church, Virginia, United States

NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study

Not Applicable

Recruiting

Conditions: Hypertrophic Cardiomyopathy
Mitral Valve Disease
Left Ventricular Septal Hypertrophy
Aortic Valve Stenosis

Interventions: Device: Septal Scoring Along Midline Endocardium

First Posted Date: 2024-02-21

Last Posted Date: 2025-05-18

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 30

Registration Number: NCT06269640

Locations: 🇺🇸
St Francis Hospital and Heart Center, Roslyn, New York, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

Phase 1

Active, not recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: Non-myeloablative haploidentical peripheral blood stem cell transplantation with briquilimab and abatacept

First Posted Date: 2023-11-24

Last Posted Date: 2025-04-10

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 6

Registration Number: NCT06145282

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

First Posted Date: 2023-10-23

Last Posted Date: 2025-04-11

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 40

Registration Number: NCT06093867

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

Phase 1

Recruiting

Conditions: Systemic Lupus Erythematosus (Sle)

Interventions: Dietary Supplement: Nicotinamide Riboside

First Posted Date: 2023-09-13

Last Posted Date: 2024-12-02

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 78

Registration Number: NCT06032923

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease

Phase 1

Completed

Conditions: Kohlmeier Degos Disease With Neurologic Involvement

Interventions: Drug: Ruxolitinib

First Posted Date: 2023-08-21

Last Posted Date: 2025-04-20

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1

Registration Number: NCT05998395

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

Phase 1

Recruiting

Conditions: Hypoplastic MDS
Single Lineage Cytopenias, T-LGL
Severe Aplastic Anemia

Interventions: Drug: Ruxolitinib

First Posted Date: 2023-08-21

Last Posted Date: 2025-03-30

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 145

Registration Number: NCT05998408

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of Intravenous ZMA001 in Healthy Subjects

Phase 1

Suspended

Conditions: Pulmonary Arterial Hypertension PAH

Interventions: Other: Placebo
Drug: ZMA001 (BC-NKA-20008)

First Posted Date: 2023-08-01

Last Posted Date: 2025-05-18

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 20

Registration Number: NCT05967299

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

Phase 1

Recruiting

Conditions: Sickle Cell Disease
Hb-SS Disease
Hemoglobin S
Disease Sickle Cell Anemia
Sickle Cell Disorders
Hemoglobin Beta Thalassemia Disease

Interventions: Drug: Fostamatinib

First Posted Date: 2023-06-15

Last Posted Date: 2025-04-20

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 25

Registration Number: NCT05904093

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia

Phase 1

Recruiting

Conditions: Steroid-refractory Diamond-Blackfan Anemia (DBA)

Interventions: Drug: Bitopertin

First Posted Date: 2023-04-25

Last Posted Date: 2025-03-26

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 30

Registration Number: NCT05828108

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy